Janux Therapeutics (JANX) investor relations material

Executive summary

• Clinical-stage biopharma advancing immunotherapies for cancer and autoimmune diseases, with TRACTr, TRACIr, and ARM platforms and multiple candidates in clinical and preclinical stages.

• Lead programs include JANX007, JANX011, and JANX014 in Phase 1 trials, with JANX013 on track for clinical initiation in the second half of 2026.

• Continued enrollment in key prostate cancer and autoimmune disease studies, with upcoming data readouts and milestones anticipated in late 2026 and early 2027.

• Revenue is derived solely from collaboration agreements with Merck and BMS; no product sales to date.

• Maintained strong liquidity with $971.7 million in cash, cash equivalents, restricted cash, and short-term investments as of June 30, 2026.

Financial highlights

• Collaboration revenue was $10.3 million for Q2 2026 and $14.0 million for the first half of 2026, up from $0 in the prior year, driven by the BMS agreement.

• Net loss for Q2 2026 was $22.0 million, an improvement from $33.9 million in Q2 2025; net loss for the first half of 2026 was $46.3 million, improved from $57.4 million in the prior year.

• Operating expenses for Q2 2026 were $42.0 million, down from $45.1 million in Q2 2025, with R&D expenses decreasing due to lower direct costs for several programs.

• Research and development expenses were $31.0 million, down from $34.7 million year-over-year; general and administrative expenses were $11.0 million, slightly up from $10.5 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $970.9 million at quarter-end, up from $966.6 million at year-end 2025.

Outlook and guidance

• Existing cash and investments are expected to fund operations and capital expenditures for at least the next 12 months.

• Anticipates continued operating losses and negative cash flows as R&D activities expand; expects to seek additional capital before any product commercialization.

• Initial clinical data from the JANX011 Phase 1 study expected in the second half of 2026; clinical initiation of JANX013 anticipated in the second half of 2026.

• Additional clinical data for JANX007 to be presented in the first half of 2027.